Does leflunomide cause kidney injury?

Does Leflunomide Cause Kidney Injury?

Leflunomide does not directly cause structural kidney injury under normal clinical use, but it requires caution in patients with renal impairment due to altered drug pharmacokinetics and limited safety data in this population.

Evidence from FDA Drug Label and Guidelines

The FDA drug label for leflunomide provides critical information about renal considerations 1:

• No direct nephrotoxicity documented: The label notes that leflunomide has a "uricosuric effect" due to specific effects on the renal proximal tubule brush border, and some patients experience hypophosphaturia. Importantly, "these effects have not been seen together, nor have there been alterations in renal function" 1.

• Renal insufficiency concerns: Single-dose studies in dialysis patients showed a doubling of the free fraction of the active metabolite (M1) in plasma. However, "there is no clinical experience in the use of leflunomide in patients with renal impairment" and "caution should be used when administering this drug in this population" 1.

• Elimination pathway: The active metabolite M1 is eliminated through both renal excretion (approximately 43% of radioactivity) and biliary excretion (48%), with renal elimination being more significant in the first 96 hours 1.

Guideline Recommendations for Monitoring

Multiple rheumatology guidelines address leflunomide monitoring but do not mandate routine renal function monitoring as a primary safety concern:

Monitoring Requirements

The 2022 ACR guidelines for juvenile idiopathic arthritis conditionally recommend monitoring CBC and liver function tests within the first 1-2 months and every 3-4 months thereafter, but do not specifically require routine creatinine or urinalysis monitoring 2, 3. This contrasts with drugs like sulfasalazine, where renal function monitoring is explicitly recommended 2.

The 2020 AAD-NPF psoriasis guidelines 4 and 2009 AAD guidelines 5 recommend:

• Baseline: CBC with differential and liver function tests
• Ongoing: Monthly CBC and LFTs for first 6 months, then every 6-8 weeks
• No specific renal monitoring is mandated

Clinical Context

The 2012 EULAR/ERA-EDTA lupus nephritis guidelines note that "data on leflunomide are limited" in the context of renal disease 6, suggesting it is not a preferred agent when kidney disease is present but not identifying it as nephrotoxic.

Research Evidence on Renal Effects

Recent preclinical studies have identified potential nephrotoxic mechanisms, but these findings are from animal models using experimental conditions:

• 2026 mouse study: Leflunomide at 10 mg/kg for 8 weeks significantly increased serum creatinine (0.88 vs 0.16 mg/dL) and BUN (69.15 vs 32.52 mg/dL) through oxidative stress and inflammatory pathways 7.

• 2025 mouse study: Chronic leflunomide exposure induced renal dysfunction characterized by oxidative stress, inflammation, and apoptosis via TLR4/MyD88/TRAF6 axis upregulation 8.

• 2010 rat study: In a model of ischemia-reperfusion injury, FK778 (a leflunomide derivative) showed "potential nephrotoxicity" at higher doses 9.

Critical caveat: These are animal studies using doses and conditions that may not reflect clinical use. The 2020 review on leflunomide in renal transplantation noted that "the available clinical data with leflunomide in renal transplantation are limited" but suggested positive outcomes, though concerns about toxicity with higher dosages have been raised 10.

Drug Interaction Considerations

Leflunomide can increase renal exposure of other drugs: A 2020 study demonstrated that leflunomide/teriflunomide inhibits OAT1/3 and MRP2 transporters, increasing kidney accumulation of acyclovir and potentially raising renal injury risk from that drug 11. This highlights the importance of considering drug-drug interactions in patients on combination therapy.

Clinical Recommendations

When to Use Leflunomide with Renal Considerations:

1. Avoid in established renal impairment: Given the lack of clinical experience and altered pharmacokinetics (doubled free fraction of M1), leflunomide should be avoided in patients with significant renal dysfunction 1.

2. Baseline assessment: Obtain baseline renal function (creatinine, estimated GFR) before initiating therapy, though this is more for establishing baseline than for routine monitoring.

3. Primary monitoring focus: Concentrate on hepatic and hematologic monitoring as these are the established toxicities:

   • Monthly CBC and LFTs for first 6 months
   • Every 6-8 weeks thereafter 5, 4, 5

4. Consider renal monitoring if:

   • Patient has pre-existing mild renal impairment
   • Concurrent use of other potentially nephrotoxic drugs
   • Concurrent use of drugs eliminated renally (dose adjustments may be needed)

5. Drug interactions: Be particularly cautious when combining leflunomide with:

   • Acyclovir or other renally eliminated antivirals 11
   • NSAIDs (extensively used concomitantly in clinical studies without differential effect, but theoretical concern) 1
   • Other immunosuppressants, especially in transplant settings 10

Common Pitfalls to Avoid:

• Do not withhold leflunomide solely due to theoretical renal concerns in patients with normal kidney function—the primary established toxicities are hepatic and hematologic.
• Do not assume leflunomide is safe in dialysis patients—the pharmacokinetics are significantly altered and clinical experience is lacking 1.
• Do not overlook the uricosuric effect—monitor for hyperuricemia in susceptible patients, though this does not represent kidney injury 1.